Insulet touts real-world data for Omnipod insulin management tech

Insulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes. The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data […]

This smart mat can predict the onset of foot ulcers

A Massachusetts Institute of Technology hackathon participant developed a smart mat that helps detect early warning signs of foot ulcers. Jon Bloom, co-founder of startup company Podimetrics, developed a mat that can detect foot ulcers before they happen and reduce the number of amputations occurring. Bloom completed his residency in anesthesiology at Massachusetts General Hospital in

Medtronic recalls insulin infusion sets

Medtronic (NYSE:MDT) said today that it’s recalling some of the infusion sets used with its insulin pumps due to problems with a discontinued component. The Fridley, Minn.-based medical device titan said the problem involves a vent membrane that’s susceptible to blockage during priming and fill-tubing. No pumps or glucose sensors are affected by the recall, Medtronic […]

Dexcom partners with Fitbit for glucose-monitoring tech

Dexcom (NSDQ:DXCM) and Fitbit (NYSE:FIT) have partnered to develop and market continuous glucose monitoring technology for people with diabetes, the companies announced today. The companies plan to integrate Dexcom’s CGM data with Fitbit’s new smartwatch, the Fitbit Ionic, so CGM users on Android or iOS devices can see their activity and glucose levels on their […]

GI Dynamics CEO is optimistic about Endobarrier’s future: Here’s why

GI Dynamics (ASX:GID) CEO Scott Schorer has had an uphill battle over the past year. His company has faced regulatory and compliance issues, negative shareholder sentiment and a number of other concerns. But Schorer and his team are committed to righting the ship and saving a product they see as having no equal in the current

One Drop touts effects of diabetes management mobile app

One Drop touted data today from a retrospective study of people with Type I and Type II diabetes using its mobile diabetes management app. The data, which were published yesterday in JMIR Diabetes, showed that people using the One Drop mobile app had a 1.1% to 1.3% absolute reduction in A1C in 4 months. Get the full

7 diagnostic devices to boost healthcare in the developing world

The World Health Organization estimates that a quarter of death and disease globally is caused by hazards and environmental burdens in developing countries with little to no access to preventative care and diagnostic devices. Since developing countries are poor agricultural regions that are still becoming economically and socially advanced, it is harder for doctors to

Pages: 1 2 3 4 5 6 7 8

Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment

Just one week after Abbott (NYSE:ABT) said it inked a deal with Bigfoot Biomedical to develop an automated diabetes management system, CEO Miles White told analysts that he thinks Bigfoot is playing an important role in the strategic change taking place in the space. “It’s a fairly clever service and approach that I think will create, not just an

How Bigfoot Biomedical wants to disrupt diabetes care

Bigfoot Biomedical is a highly competitive player in medtech’s race to develop an artificial pancreas. The 50-person company has made rapid progress towards developing a smart, automated insulin delivery system since its beginnings in 2014. Just yesterday Bigfoot announced that it is partnering with Abbott, bringing together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin

Medtech stories we missed this week: July 14, 2017

From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief

Here are the top 5 medtech stories of mid-2017

The middle of 2017 is shaping up to be a continued whirlwind of activity for medtech. FDA is getting used to its new leadership but is facing a continued lack of clarity on user fees and UDIs. Industry is seeing a deeper consolidation in medical supplies, exemplified in Cardinal Health’s purchase of patient recovery supplies from

Pages: 1 2 3 4 5 6

Analysis: Here’s why medtech should feel optimistic about 2017

Uncertainty continues to swirl around the new Trump administration, but there is a lot to be excited about in the medical device industry these days, especially when it comes to cardiology and diabetes treatment. Medtech companies are performing well. More than 80% of the world’s 100 largest medical device companies saw their stock values increase

Hydrogel tech boosts success of transplanted insulin-producing cells

A hydrogel material embedded with a protein to improve blood vessel growth may boost the success rate of transplanting insulin-producing islet cells into patients with Type I diabetes, according to a preclinical study published in the journal Science Advances.  In the newly-published work, supported by the National Institutes of Health and the Juvenile Diabetes Research Foundation,

RxFunction device helps diabetics walk again

Patients who have peripheral neuropathy as a result of diabetes have shown improvement in their gait and balance using RxFunction’s new wearable sensory prosthesis, according to a new study. A research study from Wingate University has tested the long-term benefits of using wearable technology company RxFunction’s Walkasins in people who have peripheral neuropathy. “These exciting

9 diabetes breakthroughs you need to know

Diabetes is a disease that affects the body’s ability to produce and respond to insulin. About 29.1 million people have diabetes in the U.S, according to the Centers for Disease Control and Prevention. Of that number, 8.1 million go undiagnosed. One of the most popular breakthroughs in diabetes research has been the artificial pancreas, which

Pages: 1 2 3 4 5 6 7 8 9 10